Compositions and methods for inhibiting pathogen infection
Samuel Lai, Carrboro, NC (US); Ying-Ying Wang, San Francisco, CA (US); Arthi Kannan, Morrisville, NC (US); Kenetta Nunn, Moscow, ID (US); Durai Babu Subramani, Chapel Hill, NC (US); Richard Cone, Baltimore, MD (US); Bing Yang, Chapel Hill, NC (US); and Justin Mccallen, Greenville, NC (US)
Assigned to The University of North Carolina at Chapel Hill, Chapel Hill, NC (US); and The Johns Hopkins University, Baltimore, MD (US)
Filed by The University of North Carolina at Chapel Hill, Chapel Hill, NC (US); and The Johns Hopkins University, Baltimore, MD (US)
Filed on Oct. 9, 2020, as Appl. No. 17/066,874.
Application 17/066,874 is a continuation of application No. 16/138,643, filed on Sep. 21, 2018, granted, now 10,829,543.
Application 16/138,643 is a continuation in part of application No. 14/438,511, granted, now 10,100,102, issued on Oct. 16, 2018, previously published as PCT/US2013/067328, filed on Oct. 29, 2013.
Claims priority of provisional application 62/646,220, filed on Mar. 21, 2018.
Claims priority of provisional application 61/719,689, filed on Oct. 29, 2012.
Prior Publication US 2021/0061889 A1, Mar. 4, 2021
1. A method for immobilizing or inhibiting a sexually transmitted infection by a pathogen, or reducing pathogen load in a subject in need thereof, the method comprising administering to a mucosal surface of the subject a recombinant antibody with a specific affinity for the pathogen, the recombinant antibody comprising a human or humanized Fc region, wherein the recombinant antibody comprises a population of antibodies in which at least 40% comprise an oligosaccharide having a GOF glycosylation pattern comprising a biantennary core glycan structure of Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ1 with a fucose residue and a terminal N-acetylglucosamine, wherein the terminal N-acetylglucosamine is on each branch, that enhances the trapping potency of the recombinant antibody in mucus, so that the recombinant antibody binds to the pathogen to form an antibody/pathogen complex that is trapped in the subject's mucus.